Changes in Beneficial Ownership · 4
Windward Bio Group AG
WWBNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-11162026_061101.xml
Filing details
- Report period
- 2026-11-12
- Issuer
- WINDWARD BIO GROUP AG
- Issuer CIK
- 0002145089
- Trading symbol
- WWB
Reporting owner 1
- Name
- Applebaum Scott
- Reporting owner CIK
- 0001618945
- Relationship
- Officer
- Officer title
- Chief Legal & Corp Dev Officer
- Address
- C/O WINDWARD BIO GROUP AG, AESCHENPLATZ 6, BASEL, SWITZERLAND, V8, 4052
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Shares | 2026-11-16 | A · Form 4 | 33,206[F1] | A | 0 | 960,966 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Share Option (Right to Buy) | 17 | 2026-11-12 | A · Form 4 | 180,160 | A | 0 | [F2] | 2036-11-12 | Common Shares | 180,160 | 180,160 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- Represents a restricted share unit ("RSU") award. One quarter (1/4th) of the RSU will vest on May 11, 2027, and the remainder will vest in eight substantially equal installments on each subsequent May 20, August 20, November 20 and February 20, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.↩ 1
- F2
- This option will vest in 36 substantially equal monthly installments on the last day of the relevant month commencing on December 31, 2026, subject to the Reporting Person's continuous service as of each such vesting date.↩ 1
Signature 1
- Signed
- /s/ Scott Applebaum
- Date
- 2026-11-16
Company context
We are a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, chronic obstructive pulmonary disease, or COPD, and atopic dermatitis. We estimate these diseases collectively represent a $60 billion peak market opportunity for biologic therapies, as we believe the majority of patients eligible to receive biologic treatment for these diseases remain untreated. Our product candidates can potentially address this significant unmet need, allow for treatment of a broader population of patients, improve efficacy, and improve dosing convenience and adherence to treatment. We estimate that these diseases collectively affect more than 100 million people in the United States, EU5 (France, Germany, Italy, Spain, and the United Kingdom), and Japan and more than 8 million are eligible for biologics treatment.